Mr. Seunghyun Cho
General Manager
Natuzen Co., Ltd.
289 Namdongdong-Ro
Namdong-gu
Incheon
21639
South KoreaFEI 3006731547Issued May 3, 2024Center for Drug Evaluation and Research | CDER
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3006731547.
Violations4
Issue DateMay 3, 2024
Product TypeDrugs
StatusClosed
Closeout LetterMar 11, 2025
Letter Details
Firm
Natuzen Co., Ltd.
Location
Mr. Seunghyun Cho
General Manager
Natuzen Co., Ltd.
289 Namdongdong-Ro
Namdong-gu
Incheon
21639
South Korea
FEI Number
3006731547
Country
South Korea
Issue Date
May 03, 2024
Issuing Office
Center for Drug Evaluation and Research | CDER
Product Type
Drugs
Status
Closed
Closeout Letter
March 11, 2025
Summary
Natuzen Co., Ltd., a South Korean manufacturer of over-the-counter drug products including Atoren Hand Sanitizer, violated Current Good Manufacturing Practice (CGMP) regulations, rendering their products adulterated. The company failed to conduct required identity testing of drug components, specifically failing to test their ethanol active ingredient for methanol contamination, citing a Korean regulatory notification as justification rather than performing independent verification. This testing gap meant the firm lacked scientific evidence that raw materials conformed to appropriate specifications before use in manufacturing. The warning was issued following FDA's review of records submitted in response to multiple requests dating back to March 2022.